ABVC BioPharma ABVC
單位：USD
0.98
0.07
(7.19%)
單位：美金千元
| 科目 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | 2023/Q4 | 2023/Q3 | 2023/Q2 | 2023/Q1 | 2022/Q4 | 2022/Q3 | 2022/Q2 | 2022/Q1 | 2021/Q4 | 2021/Q3 | 2021/Q2 | 2021/Q1 | 2020/Q4 | 2020/Q3 | 2020/Q2 | 2020/Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
營業收入淨額
| 2 | 389 | 117 | 1 | 2 | 16 | 6 | 128 | 589 | 42 | 313 | 26 | -38 | 99 | 31 | 263 | 62 | 116 | 227 | 79 |
營業成本
| - | - | - | - | 139 | 30 | 73 | 60 | 265 | 11 | 8 | 2 | 3 | - | 1 | 1 | 2 | 9 | 4 | 4 |
營業毛利
| 2 | 389 | 117 | 1 | -137 | -14 | -67 | 68 | 324 | 32 | 304 | 24 | -41 | 99 | 31 | 262 | 60 | 107 | 222 | 75 |
營業費用
| 336 | 339 | 1,093 | 3,445 | 1,824 | 2,141 | 2,127 | 1,974 | 3,457 | 3,747 | 2,352 | 6,242 | 6,302 | 2,069 | 2,066 | 1,514 | 4,911 | 1,397 | 1,416 | 1,246 |
研發費用
| 32 | 38 | 40 | 69 | 72 | 141 | 514 | 335 | 1,496 | 305 | 533 | 359 | 260 | 263 | 359 | 121 | 183 | 135 | 139 | 93 |
推銷及管理費用
| 304 | 301 | 1,053 | 3,376 | 1,752 | 2,000 | 1,613 | 1,639 | 1,961 | 3,442 | 1,819 | 5,883 | 6,146 | 1,806 | 1,707 | 1,393 | 4,728 | 1,262 | 1,277 | 1,153 |
非經常性項目費用
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
其他營業費用
| - | - | - | - | - | - | - | - | - | - | - | - | -104 | - | - | - | - | - | - | - |
營業利益
| -334 | 50 | -977 | -3,444 | -1,962 | -2,155 | -2,194 | -1,906 | -3,133 | -3,716 | -2,047 | -6,219 | -6,343 | -1,971 | -2,036 | -1,253 | -4,851 | -1,290 | -1,194 | -1,171 |
其他收入及費用
| 317 | 104 | -68 | 148 | 132 | 4 | 75 | 66 | -271 | 70 | 32 | 62 | - | 139 | 59 | 184 | 13 | 17 | -789 | 23 |
利息費用
| -338 | 220 | 260 | 685 | 1,103 | 1,219 | 115 | 57 | 134 | 127 | 15 | 18 | -24 | 39 | 83 | 130 | 117 | 16 | 141 | 132 |
稅前純益
| 129 | -134 | -1,384 | -3,981 | -3,154 | -3,369 | -2,234 | -1,897 | -3,538 | -3,772 | -2,030 | -6,174 | -5,890 | -1,962 | -2,113 | -1,246 | -5,056 | -2,176 | -2,233 | -1,350 |
所得稅
| - | - | -111 | - | 175 | -1 | 82 | - | 963 | 4 | -82 | -87 | 1,011 | -76 | -60 | -51 | -86 | -45 | -49 | -41 |
稅後純益
| 229 | -187 | -1,013 | -3,933 | -3,111 | -3,318 | -2,264 | -1,824 | -4,864 | -3,705 | -1,859 | -5,995 | -7,932 | -1,806 | -1,972 | -1,129 | -4,848 | -1,846 | -1,849 | -1,248 |
基本每股稅後盈餘(元)
| 0.09 | -0.02 | -0.09 | -0.4 | - | -0.82 | -0.07 | -0.06 | -0.15 | -0.11 | -0.06 | -0.2 | - | -0.07 | -0.08 | -0.05 | - | -0.09 | -0.09 | - |
稀釋每股稅後盈餘(元)
| 0.04 | 0.01 | -0.07 | -0.4 | 0.28 | -0.84 | -0.07 | -0.06 | -0.15 | -0.11 | -0.07 | -0.2 | - | -0.07 | -0.08 | -0.05 | -0.25 | -0.09 | -0.1 | -0.06 |
基本平均股數(千股)
| 13,233 | 12,405 | 11,321 | 9,736 | - | 4,055 | 33,087 | 33,075 | 33,078 | 32,579 | 31,307 | 29,683 | - | 26,882 | 24,421 | 24,420 | - | 19,488 | 19,488 | - |
稀釋平均股數(千股)
| 13,233 | 12,405 | 11,321 | 9,736 | - | 4,055 | 33,087 | 33,075 | 33,078 | 32,579 | 31,307 | 29,683 | - | 26,882 | 24,421 | 24,420 | - | 19,488 | 19,488 | - |
還原基本每股稅後盈餘(元)
| 0.09 | -0.02 | -0.09 | -0.4 | - | -0.82 | -0.68 | -0.55 | -1.5 | -1.14 | -0.59 | -2 | - | -0.7 | -0.8 | -0.5 | - | -0.9 | -0.9 | - |
還原稀釋每股稅後盈餘(元)
| 0.04 | 0.01 | -0.07 | -0.4 | 0.28 | -0.84 | -0.69 | -0.55 | -1.48 | -1.06 | -0.65 | -2 | - | -0.7 | -0.8 | -0.5 | -2.5 | -0.9 | -1 | -0.6 |
還原基本平均股數(千股)
| 13,233 | 12,405 | 11,321 | 9,736 | - | 4,055 | 3,308 | 3,307 | 3,307 | 3,257 | 3,130 | 2,968 | - | 2,688 | 2,442 | 2,442 | - | 1,948 | 1,948 | - |
還原稀釋平均股數(千股)
| 13,233 | 12,405 | 11,321 | 9,736 | - | 4,055 | 3,308 | 3,307 | 3,307 | 3,257 | 3,130 | 2,968 | - | 2,688 | 2,442 | 2,442 | - | 1,948 | 1,948 | - |
EBITDA(千元)
| 70 | 40 | -851 | -3,247 | -1,825 | -2,093 | -2,060 | -1,761 | -3,761 | -3,568 | -1,921 | -6,059 | -6,942 | -1,840 | -1,946 | -1,047 | -4,810 | -1,866 | -1,747 | -1,146 |